Johnson & Johnson: Among patients with early recurrent or refractory multiple myeloma, 50% of patients with CARVYKTI achieved remission without treatment for 5 years.

Zhitongcaijing · 1d ago
Johnson & Johnson: Among patients with early recurrent or refractory multiple myeloma, 50% of patients with CARVYKTI achieved remission without treatment for 5 years.